Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and
safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib
(LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or
IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous
systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
National Cancer Institute (NCI)
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and
MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to
other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may
stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving
LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time
when tumors become resistant to the drugs.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.